Search Results

You are looking at 31 - 40 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

, University of Washington; Co-Director, Melanoma Clinic, Seattle Cancer Care Alliance; and Chair of the NCCN Guidelines Panel for Management of Immunotherapy-Related Toxicities. NCCN in collaboration with ASCO developed a standardized approach for the

Full access

Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer

Xiuning Le, Renata Ferrarotto, Trisha Wise-Draper, and Maura Gillison

cetuximab. 14 , 15 Until 2016, the second-line options after platinum-containing regimen were limited to monotherapy, including a taxane, methotrexate, or cetuximab. Initial Success of Anti–PD-1 Therapy in R/M SCCHN Immunotherapy with immune checkpoint

Full access

Integrating Immunotherapy Into the Management of Renal Cell Carcinoma

Matthew Zibelman and Elizabeth R. Plimack

The emergence of immunotherapy heralded by drugs targeting immune checkpoints has generated tremendous promise across the oncology community and dramatically altered the therapeutic landscape of many malignancies. Management of renal cell

Full access

Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance

Agata A. Bielska, Walid K. Chatila, Henry Walch, Nikolaus Schultz, Zsofia K. Stadler, Jinru Shia, Diane Reidy-Lagunes, and Rona Yaeger

“non-self” immunogenic antigens, high lymphocyte infiltration, and immune response. 5 , 6 Because of the high immunogenicity of these tumors, microsatellite instability–high (MSI-H) or dMMR cancers have been shown to respond well to immunotherapy, in

Full access

Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options

Kelly N. Fitzgerald and Chung-Han Lee

separated by at least 6 months of overall survival (OS) time. Importantly, the MSKCC system was developed before the modern era of TKI and immunotherapy, and therefore median OS for each risk category was lower than what is currently expected. Categories

Full access

Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time

Amanda Putri Rahmadian, Seanthel Delos Santos, Shruti Parshad, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan

Background In recent years, immunotherapy has emerged as an alternative to chemotherapy and has been commonly viewed as a “game changer” for its potential to improve survival in a small proportion of patients. 1 – 4 Randomized controlled trials

Full access

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand, Meghan K. Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan McPherson, Theresa Medina, Nisha A. Mohindra, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Pradnya Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary Dwyer, and Lisa Hang

Overview CAR T cells represent a newer class of immunotherapy agents that is increasingly being incorporated into the treatment regimens of certain refractory or relapsed hematologic malignancies, specifically subtypes of B-cell non

Full access

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J. Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, and Jillian L. Scavone

Overview The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. The NCCN Management of Immunotherapy

Full access

Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma

Matthew Zibelman and Anthony J. Olszanski

highlights the full spectrum of clinical responses that are possible with the new generation of immunotherapies in metastatic melanoma—from rapidly developing and unpredictable irAEs to impressive and durable disease regressions. Melanoma incidence has been

Full access

Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

, treatment options remain limited. This report presents 3 patients with dMMR locally advanced adenocarcinoma of the rectum who experienced significant response to single-agent immunotherapy or combination neoadjuvant immuno/chemotherapy, and briefly reviews